{Reference Type}: Journal Article
{Title}: Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
{Author}: Catalano F;Brunelli M;Signori A;Rescigno P;Buti S;Galli L;Spada M;Masini C;Galuppini F;Vellone VG;Gaggero G;Maruzzo M;Merler S;Vignani F;Cavo A;Bimbatti D;Milella M;Dei Tos AP;Sbaraglia M;Murianni V;Damassi A;Cremante M;Maffezzoli M;Llaja Obispo MA;Banna GL;Fornarini G;Rebuzzi SE;
{Journal}: Future Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 3
{Factor}: 3.674
{DOI}: 10.1080/14796694.2024.2340960
{Abstract}: Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.